A critical role for thioredoxin- Interacting protein in diabetes-related impairment of angiogenesis

Diabetes

Volumn 63, Issue 2, 2014, Pages 675-687

  Dunn, Louise L ^a,b   Simpson, Philippa J L ^a   Prosser, Hamish C ^a   Lecce, Laura ^a   Yuen, Gloria S C ^a,b   Buckle, Andrew ^a   Sieveking, Daniel P ^a   Vanags, Laura Z ^a   Lim, Patrick R ^a   Chow, Renee W Y ^a   Lam, Yuen Ting ^a   Clayton, Zoe ^a   Bao, Shisan ^b   Davies, Michael J ^a,b   Stadler, Nadina ^a   Celermajer, David S ^a,b,c   Stocker, Roland ^d   Bursill, Christina A ^a   Cooke, John P ^e   Ng, Martin K C ^a,b,c  

^a HEART RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; SMALL INTERFERING RNA; STREPTOZOCIN; THIOREDOXIN INTERACTING PROTEIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW; CELL FUNCTION; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIUM CELL; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VIVO STUDY; LIMB ISCHEMIA; MALE; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SENSITIVITY ANALYSIS; SURVIVAL;

ANIMALS; BLOOD GLUCOSE; CARRIER PROTEINS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; GENE SILENCING; GLUCOSE; HUMANS; MALE; MICE; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; SIGNAL TRANSDUCTION; THIOREDOXINS;

EID: 84893082315     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-0417     Document Type: Article

References (35)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-2038
2. Abaci A, Oguzhan A, Kahraman S, et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 1999;99:2239-2242
3. Jonasson JM, Ye W, Sparén P, Apelqvist J, Nyrén O, Brismar K. Risks of nontraumatic lower-extremity amputations in patients with type 1 diabetes: a population-based cohort study in Sweden. Diabetes Care 2008;31:1536-1540
4. Rivard A, Silver M, Chen D, et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999;154:355-363
5. Waltenberger J, Lange J, Kranz A. Vascular endothelial growth factor-Ainduced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: A potential predictor for the individual capacity to develop collaterals. Circulation 2000;102:185-190
6. Dunn LL, Buckle AM, Cooke JP, Ng MK. The emerging role of the thioredoxin system in angiogenesis. Arterioscler Thromb Vasc Biol 2010;30: 2089-2098
7. Minn AH, Hafele C, Shalev A. Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces betacell apoptosis. Endocrinology 2005;146:2397-2405
8. Parikh H, Carlsson E, Chutkow WA, et al. TXNIP regulates peripheral glucose metabolism in humans. PLoS Med 2007;4:e158
9. Schulze PC, Yoshioka J, Takahashi T, He Z, King GL, Lee RT. Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem 2004;279:30369-30374
10. Ng MK, Wu J, Chang E, et al. A central role for nicotinic cholinergic regulation of growth factor-induced endothelial cell migration. Arterioscler Thromb Vasc Biol 2007;27:106-112
11. Yoshioka J, Chutkow WA, Lee S, et al. Deletion of thioredoxin-interacting protein in mice impairs mitochondrial function but protects the myocardium from ischemia-reperfusion injury. J Clin Invest 2012;122:267-279
12. Yoshioka J, Imahashi K, Gabel SA, et al. Targeted deletion of thioredoxininteracting protein regulates cardiac dysfunction in response to pressure overload. Circ Res 2007;101:1328-1338
13. Farrell MR, Rogers LK, Liu Y, Welty SE, Tipple TE. Thioredoxin- interacting protein inhibits hypoxia-inducible factor transcriptional activity. Free Radic Biol Med 2010;49:1361-1367
14. Spindel ON, World C, Berk BC. Thioredoxin interacting protein: redox dependent and independent regulatory mechanisms. Antioxid Redox Signal 2012;16:587-596
15. Saxena G, Chen J, Shalev A. Intracellular shuttling and mitochondrial function of thioredoxin-interacting protein. J Biol Chem 2010;285:3997-4005
16. Sieveking DP, Buckle A, Celermajer DS, Ng MK. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J Am Coll Cardiol 2008;51:660-668
17. Holmgren A, Björnstedt M. Thioredoxin and thioredoxin reductase. Methods Enzymol 1995;252:199-208
18. Chutkow WA, Patwari P, Yoshioka J, Lee RT. Thioredoxin-interacting protein (Txnip) is a critical regulator of hepatic glucose production. J Biol Chem 2008;283:2397-2406
19. Sekyere EO, Dunn LL, Suryo Rahmanto Y, Richardson DR. Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in vivo. Blood 2006;107:2599-2601
20. Pautsch A, Stadler N, Wissdorf O, Langkopf E, Moreth W, Streicher R. Molecular recognition of the protein phosphatase 1 glycogen targeting subunit by glycogen phosphorylase. J Biol Chem 2008;283:8913-8918
21. Pfaffl MW. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res 2001;29:e45
22. Bosch-Marce M, Okuyama H, Wesley JB, et al. Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. Circ Res 2007;101:1310-1318
23. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
24. Patel KL. Impact of tight glucose control on postoperative infection rates and wound healing in cardiac surgery patients. J Wound Ostomy Continence Nurs 2008;35:397-404; quiz 405-406
25. Basile DP, Fredrich K, Weihrauch D, Hattan N, Chilian WM. Angiostatin and matrix metalloprotease expression following ischemic acute renal failure. Am J Physiol Renal Physiol 2004;286:F893-F902
26. Selvin E, Wattanakit K, Steffes MW, Coresh J, Sharrett AR. HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 2006;29:877-882
27. Yang Z, Mo X, Gong Q, et al. Critical effect of VEGF in the process of endothelial cell apoptosis induced by high glucose. Apoptosis 2008;13: 1331-1343
28. Cooke JP, Losordo DW. Nitric oxide and angiogenesis. Circulation 2002; 105:2133-2135
29. Cai S, Khoo J, Channon KM. Augmented BH4 by gene transfer restores nitric oxide synthase function in hyperglycemic human endothelial cells. Cardiovasc Res 2005;65:823-831
30. Perrone L, Devi TS, Hosoya K, Terasaki T, Singh LP. Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions. J Cell Physiol 2009;221:262-272
31. Samuel SM, Thirunavukkarasu M, Penumathsa SV, et al. Thioredoxin-1 gene therapy enhances angiogenic signaling and reduces ventricular remodeling in infarcted myocardium of diabetic rats. Circulation 2010;121: 1244-1255
32. Dai S, He Y, Zhang H, et al. Endothelial-specific expression of mitochondrial thioredoxin promotes ischemia-mediated arteriogenesis and angiogenesis. Arterioscler Thromb Vasc Biol 2009;29:495-502
33. Patwari P, Chutkow WA, Cummings K, et al. Thioredoxin-independent regulation of metabolism by the alpha-arrestin proteins. J Biol Chem 2009; 284:24996-25003
34. Shin D, Jeon JH, Jeong M, et al. VDUP1 mediates nuclear export of HIF1alpha via CRM1-dependent pathway. Biochim Biophys Acta 2008; 1783:838-848
35. Park SY, Shi X, Pang J, Yan C, Berk BC. Thioredoxin-interacting protein mediates sustained VEGFR2 signaling in endothelial cells required for angiogenesis. Arterioscler Thromb Vasc Biol 2013;33:737-743